Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 66.74B 58.62B 54.51B 50.02B 93.99B 6,427B 95.44B 647B 253B 3,160B 251B 245B 10,925B P/E 2026 *
17.3x
P/E 2027 * 13.8x
Enterprise Value 58.92B 51.75B 48.13B 44.16B 82.98B 5,674B 84.25B 571B 223B 2,790B 221B 216B 9,645B EV / Sales 2026 *
3.71x
EV / Sales 2027 * 3.19x
Free-Float
72.33%
Yield 2026 *
0.59%
Yield 2027 * 0.67%
1 day+0.63%
1 week-3.06%
Current month+5.21%
1 month+5.78%
3 months-12.71%
6 months-12.94%
Current year-15.01%
1 week 637.8
Extreme 637.8
681.74
1 month 622.29
Extreme 622.29
691.13
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
2/7/26 Sell

Director

-200 0.0002%
1/5/26 Sell

Director

-100 0.0001%
1/4/26 Sell

Director

100 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%-3.06%+16.50%-10.12% 66.74B
+1.23%+2.80%+38.09%+200.66% 53.32B
+10.08%+51.80%+51.80%+51.80% 48.12B
-1.32%-7.38%-57.37%-56.96% 38.25B
+0.78%-1.84%+53.73%-25.20% 29.85B
+0.84%+0.36%+67.62%+84.46% 23.51B
-5.17%-12.54%+58.33%-55.63% 21.45B
-1.21%+1.12%+0.90%+164.17% 19.97B
+1.31%+3.24%+81.47%+157.97% 16.47B
-0.22%-0.95%+62.78%+123.12% 16.38B
Average +0.69%-0.57%+37.38%+63.43% 33.41B
Weighted average by Cap. +1.40%+0.06%+30.72%+54.70%

Financials

2026 *2027 *
Net sales 15.87B 13.94B 12.96B 11.9B 22.35B 1,529B 22.7B 154B 60.15B 751B 59.59B 58.3B 2,598B 17.61B 15.47B 14.38B 13.2B 24.8B 1,696B 25.18B 171B 66.72B 834B 66.1B 64.68B 2,882B
Net income 3.98B 3.49B 3.25B 2.98B 5.6B 383B 5.69B 38.57B 15.07B 188B 14.93B 14.61B 651B 5.03B 4.41B 4.1B 3.77B 7.08B 484B 7.19B 48.74B 19.04B 238B 18.87B 18.46B 823B
Net Debt -7.82B -6.87B -6.39B -5.86B -11.02B -753B -11.19B -75.88B -29.64B -370B -29.37B -28.73B -1,281B -10.51B -9.23B -8.59B -7.88B -14.81B -1,012B -15.03B -102B -39.84B -498B -39.47B -38.62B -1,721B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
24/07/26 USD 656.01 +0.63% 708,392
23/07/26 USD 651.91 +0.11% 1,129,411
22/07/26 USD 651.18 -3.56% 872,170
21/07/26 USD 675.19 +0.45% 529,783
20/07/26 USD 672.15 -0.67% 624,791
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
656.01USD
Average target price
819.25USD
Spread / Average Target
+24.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock